Member Info for Jatw

Lucky guess....Who knows which way the Asian UK and US markets will go at the moment.

This virus will initiate change in many countries in terms of public health practices and healthcare systems. I predict China will put a lot of effort into cleaning up its public spaces and more money into healthcare for its people. Who knows maybe the US will get the message too.
Greater demands for public healthcare will expand demand and volume at reasonable prices. HCM to be included in the Winners list.

Yesterday’s nasdaq fall looks significantly over done. Speculating I know but would not be surprised for it to rise 10% on opening in US today.

On a positive note, the recent fund raising now looks like a stroke of genius....no need to tap the market any time soon....

And here I was thinking that HCM is nearly as virus proof as it was brexit proof.
But I guess that if all the main players are down by 20% then the price for future profits also inevitably falls.
What I am hoping is that the pipeline and future progress results in a strong recovery. The investment horizon for HCM has always been 5-10 years for me....so nothing really has changed apart from the weighing machine being a bit wonky at the moment.

Yippee.....a company meeting its plans and positive capital generation is a good step.
Well on its way to organic positive capital generations as set out earlier.

Unfortunately the markets are tanking...just needs calmer waters....

BBD you have extrapolated my comment too far.
On XD date the value of the divi will come off the sp.....there may be some additional market movement. If you reinvest dividends then you will be out of the market for a few weeks and who knows what price you will pay..

If you are committing new money I would wait until XD and buy XD as the sp is unlikely to bounce much in this time and you will in effect be reinvesting the divi you would have got earlier....
Who knows which strategy will work best.....

I prefer to consider TSR....which makes a dividend payment less relevant.

However shares that can pay sustainable and growing dividends are rare and should be highly valued.
MNG has the potential to expand its franchise and to grow the dividend.....it may be yielding 10% today, but in the very short term the next dividend is not relevant for new investors.

Strong results esp from Asia. As ever there seems to be strength in a diverse set of markets.

This is turning into a real bargain.....I remember Pru hitting 190 back in 2008.....I don’t think it will get that bad this time around, but in 10 years time with 12-15% compound growth this will be seen as a huge buying opportunity (maybe not just yet...but once the virus starts to abate)

Ignore the dividend, in current conditions it will be a straight deduction from the share price.

Buy post dividend and IF the dividend is as expected next year then you will get a good 10%yield but the likelihood is that it is money back rather than income + capital retained

Not moving the dial yet.....but with the pipeline news expected re Savo and others there should be further uplifts coming....meanwhile the shares are -30% against valuation. Given the assumptions in the valuation there may be reluctance to approach these valuations....however all good for the moment and set for capital gains..

A company that is delivering on its objectives.....what more could be wanted.
The targets for 2020 would seem to be achievable/almost baked in. Although the duration of drug development means there is little that can be done to accelerate the business plan.
HCM is still a relative minnow and as an investment asset of CKHH it is subject to a potential sale if CKHH needs the cash. Hence I recommend investors to follow CKHH.

Mng suffers a double whammy when markets fall....AUM falling reduces income and the insurance solvency ratio will also fall. YE 19 valuations should be ok, but the outlook with sustained market falls would be more problematic.
Covid19 has been delayed and may be dampened in effect...the govt has a difficult job.. do they prioritise the old and the sick who may die against economic disruption and the jobs/wealth represented by the stock market....but really small and medium enterprises that have limited resources. If one group suffers the govt priorities will be wrong, so both need to suffer pain so that the govt can blame the virus.

Looks like HCM is in rude health.
Pipeline growing, including a surprise return of savoir data
Fruquintinib sales strengthening
Surufatinib heading towards launch
Sufficient cash resources.....
Market appears to like it.....could be a second strong day in a row

7% gain and back over 25$
Tomorrow results will have some interesting points to note including
Sales of fruquintinib in H2.....was it achieving volume even before NRDL for this year.
Pipeline news on Savo and progress of NDA for Surufatinib
Possible adverse impact of corona virus on China trials (hopefully reassurance of limited effect)
Cash resources
M&A progress..

BBD I have Pru comfortably ahead of MNG at -12% v -18%. These are from a holding split on demerger...... must admit I thought Pru would end the year higher than MNG but not by this route.

Crazy IFRS accounting.....sell a 12% stake realise a gain that is 25% of the market cap.....should be able to recognise the increase in value and retain the original holding.

This announcement is made by CK Hutchison Holdings Limited (the “Company”, together with its subsidiaries, the “Group”).
Reference is made to Husky Energy’s 2019 Fourth Quarter and Annual Results released on 27 February 2020.
Husky recognized total non-cash asset impairments and other charges aggregating C$2.3 billion (after tax) in the fourth quarter of 2019. These were primarily related to the Company’s upstream assets in North America, including the Sunrise Energy Project and the Atlantic and Western Canada segments, and were largely due to lower long-term commodity price assumptions and a reduction in future capital spending. The reduction in future capital spending has the effect of reducing reserves, which in turn reduces asset values. Other charges included exploration-related write-downs and asset de-recognition at the Lima Refinery associated with redundant equipment following the completion of the crude oil flexibility project.
The Group’s share of these losses after consolidation adjustments will be included in the Group’s 2019 results. For EBITDA, the Group’s share of Husky’s non-cash losses will be approximately HK$5,983 million and will be fully offset by a disposal gain of approximately HK$6,885 million arising from the derecognition of Hutchison China MediTech Limited as a subsidiary to a 49.86% associated company, following the Group’s partial disposal of interests in October 2019. As a result, the Group’s 2019 profitability is not negatively affected by these losses.

Well done, hope your purchase proves to be a bargain

The trouble is once you start down the separation route it is hard to stop other regions breaking off.

I can’t see Jackson staying with Pru too long

The change to the YE results presentation may mean we have seen the last London event.

If there is a HK listing, it would make sense for that to become the primary listing over time and London trading is increasingly irrelevant in driving the price. It makes sense to broadcast from HK

Buy the dips....or will it be a corona induced slump?
Either way the long term trend will be for more healthcare spending in China...on the type of effective treatments being developed by HCM